CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) was upgraded by analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a research note issued to investors on Tuesday, Marketbeat reports. The firm currently has a $3.50 price objective on the biotechnology company’s stock, up from their prior price objective of $2.25. Piper […]

Related Keywords

Piper Sandler , Seana Mccarthy , Cytomx Therapeutics Inc , Congress Park Capital , Jefferies Financial Group , Cytomx Therapeutics Company Profile , Susquehanna Fundamental Investments , Jpmorgan Chase Co , York Mellon Corp , Sg Americas Securities , Alphamark Advisors , Cytomx Therapeutics , Get Free Report , Financial Group , Mark Advisors , Fundamental Investments , Spark Capital , New York Mellon Corp , Cytomx Therapeutics Daily ,